Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 2,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Insulin Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")

NCT04398030
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes
Interventions
coil-reinforced soft polymer indwelling cannula, soft Teflon indwelling catheter
Device
Lead sponsor
Capillary Biomedical, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Study in Patients With Type 1 Diabetes Mellitus

NCT02459899
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Concord, California • Ventura, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 17, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Isocaloric Ultra Processed Versus Unprocessed Diets on Insulin Sensitivity

NCT03189121
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 17, 2026, 5:11 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

NCT04532801
View directory record Official record
Conditions
Insulin, Glucose, Healthy Volunteers, Women, Pregnancy
Interventions
Kisspeptin-10, mixed meal tolerance test
Drug · Other
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional

A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B

NCT05343065
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
BlueStar 10
Device
Lead sponsor
Welldoc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Phase 2 Interventional

Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects

NCT00478322
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Placebo, INCB013739
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Chula Vista, California • The Bronx, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 17, 2026, 5:11 AM EDT
Terminated Not applicable Interventional Results available

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

NCT02701257
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon, Lilly glucagon, iLet infusion set, Contact Detach infusion set
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

NCT00065130
View directory record Official record
Conditions
Diabetes, Gestational Diabetes
Interventions
human insulin, insulin NPH, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)

NCT03168867
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
The 3Ms Intervention
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 15 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Chicago, Illinois • Detroit, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men

NCT00470990
View directory record Official record
Conditions
Hypogonadism
Interventions
GnRH antagonist (Acyline)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Alogliptin Pediatric Study

NCT02856113
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin Benzoate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
10 Years to 17 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
34
States / cities
Little Rock, Arkansas • Los Angeles, California • Palmdale, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 17, 2026, 5:11 AM EDT
Not listed Phase 2 Interventional

Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2

NCT00654797
View directory record Official record
Conditions
Critically Ill, Hyperglycemia
Interventions
glucose control with computer generated recommendations
Procedure
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
1 Month and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
10
States / cities
Madera, California • Saint Paul, Minnesota • Lebanon, New Hampshire + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker

NCT01582139
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Heart rate informed SSM+HMM
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

NCT00662857
View directory record Official record
Conditions
Diabetes Mellitus: Type 1
Interventions
Technosphere Insulin® Inhalation Powder, RAA Population
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 17, 2026, 5:11 AM EDT
Terminated Not applicable Interventional

Intracutaneous Sterile Water Injections for Acute Low Back Pain in the Emergency Department

NCT04240483
View directory record Official record
Conditions
Low Back Pain
Interventions
Intracutaneous sterile water injections (ISWI) group, Intracutaneous dry injections (IDI) group
Other
Lead sponsor
Lindsey schmelzer
Federal
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Phase 1 Interventional Results available

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

NCT03095651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

NCT01683266
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
82
States / cities
Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)

NCT00907153
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Vitamin D, Placebo
Dietary Supplement · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 17, 2026, 5:11 AM EDT
Recruiting Phase 2 Interventional

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

NCT05660083
View directory record Official record
Conditions
HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
Interventions
L-NMMA
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The CARING Study: Creating and Restoring Health Through Nutrition Guidance

NCT05795439
View directory record Official record
Conditions
Type2diabetes, Type 2 Diabetes Treated With Insulin
Interventions
Low-fat, vegan diet
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

NCT06269107
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
IcoSema, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Concord, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles

NCT01231984
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Escondido, California • Atlanta, Georgia • Springfield, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional

Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis

NCT03868592
View directory record Official record
Conditions
Obesity, Morbid
Interventions
Gastric sleeve/bariatric surgery
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 17, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring

NCT07254364
View directory record Official record
Conditions
Insulin Response, Type 1 Diabetes
Interventions
Standardized meal 1
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 5:11 AM EDT